<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00898027</url>
  </required_header>
  <id_info>
    <org_study_id>VICC GI 0615</org_study_id>
    <secondary_id>VU-VICC-GI-0615</secondary_id>
    <secondary_id>VU-VICC-IRB-060364</secondary_id>
    <nct_id>NCT00898027</nct_id>
  </id_info>
  <brief_title>Effect of Epidermal Growth Factor Receptor Inhibitors on Magnesium Homeostasis in Patients With Cancer</brief_title>
  <official_title>Pilot Study of the Effects of Epidermal Growth Factor Receptor (EGFR) Inhibitors on Magnesium Homeostasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of blood and urine in the laboratory from patients with cancer&#xD;
      receiving epidermal growth factor receptor inhibitors may help doctors understand the effect&#xD;
      of epidermal growth factor receptor inhibitors on magnesium levels in the body.&#xD;
&#xD;
      PURPOSE: This laboratory study is looking at the effect of epidermal growth factor receptor&#xD;
      inhibitors on magnesium homeostasis in patients with cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the effects of EGFR inhibitors on magnesium homeostasis in patients with&#xD;
           cancer.&#xD;
&#xD;
      OUTLINE: This is a pilot study.&#xD;
&#xD;
      Patients undergo blood and urine sample collection at baseline and at 2, 4, and 8 weeks&#xD;
      during treatment.&#xD;
&#xD;
      After finishing treatment, patients are followed periodically for up to 10 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow accrual&#xD;
  </why_stopped>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of EGFR inhibitors on magnesium homeostasis</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <enrollment type="Actual">10</enrollment>
  <condition>Solid Tumor</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>laboratory biomarker analysis</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with the diagnosis of a malignancy for which they are considering therapy with&#xD;
        an inhibitor of the EGFR pathway, have received an inhibitor of the EGFR pathway prior to&#xD;
        study start, have no severe underlying renal dysfunction as defined as estimated GFR&lt;60 by&#xD;
        MDRD equation and must be ≥ 18 years of age.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of malignancy&#xD;
&#xD;
               -  Planning to receive therapy with an inhibitor of the EGFR pathway (either on or&#xD;
                  off a clinical trial and may be monotherapy or combined with other therapies)&#xD;
&#xD;
          -  Normal serum magnesium level&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Glomerular filtration rate ≥ 60 mL/min&#xD;
&#xD;
          -  No severe underlying renal dysfunction&#xD;
&#xD;
          -  Normal serum potassium and calcium level&#xD;
&#xD;
          -  No history of primary or secondary hyperparathyroidism&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior EGFR pathway inhibitor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Goff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>January 28, 2013</last_update_submitted>
  <last_update_submitted_qc>January 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Laura W. Goff, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine; Associate Director, Hematology/Oncology</investigator_title>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

